Miloš Grujić//LinkedIn
Apr 20, 2025, 08:16
Miloš Grujić: Which biopsy approach is better – LATP or TRUS?
Miloš Grujić, Radiation Oncologist at the University Clinical Center Kragujevac, shared an article by Richard J Bryant, et al. on LinkedIn:
“Which biopsy approach is better—LATP or TRUS?
The TRANSLATE trial, just published in The Lancet Oncology, provides compelling evidence in favor of local anaesthetic transperineal (LATP) biopsy over traditional transrectal ultrasound-guided (TRUS) biopsy in biopsy-naïve men.
Key findings:
LATP detected more clinically significant prostate cancers (GGG ≥2):
- 60.1% vs 54.4% with TRUS (OR 1.32, p=0.031)
- Fewer hospitalizations for post-biopsy infections with LATP.
- Comparable rates of complications and quality-of-life metrics.
- LATP had slightly more post-procedure discomfort, but fewer longer-term symptoms.
These results provide level 1 evidence supporting LATP as a preferred option, especially in the MRI-targeted diagnostic pathway.
Bryant et al., Lancet Oncology, 2025.
Visual by Dr. Miloš Grujić.”
Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.
Authors: Richard J Bryant, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023